Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 10 studies | 24% ± 6% | |
intestine | 9 studies | 21% ± 6% | |
liver | 5 studies | 36% ± 20% | |
peripheral blood | 5 studies | 29% ± 4% | |
kidney | 5 studies | 18% ± 2% | |
brain | 5 studies | 22% ± 5% | |
pancreas | 4 studies | 33% ± 18% | |
uterus | 3 studies | 37% ± 13% | |
prostate | 3 studies | 26% ± 8% | |
lymph node | 3 studies | 21% ± 2% | |
breast | 3 studies | 21% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 33485.79 | 226 / 226 | 32% | 1.17 | 130 / 406 |
esophagus | 100% | 5853.76 | 1440 / 1445 | 11% | 0.24 | 21 / 183 |
stomach | 99% | 7221.95 | 357 / 359 | 8% | 0.17 | 24 / 286 |
lung | 99% | 7690.66 | 574 / 578 | 7% | 0.13 | 79 / 1155 |
intestine | 100% | 7847.99 | 965 / 966 | 4% | 0.08 | 22 / 527 |
uterus | 100% | 4828.45 | 170 / 170 | 3% | 0.05 | 14 / 459 |
bladder | 100% | 6670.38 | 21 / 21 | 1% | 0.02 | 7 / 504 |
adrenal gland | 100% | 15545.03 | 258 / 258 | 1% | 0.02 | 2 / 230 |
breast | 100% | 5747.35 | 459 / 459 | 1% | 0.01 | 6 / 1118 |
pancreas | 99% | 6882.12 | 326 / 328 | 1% | 0.02 | 2 / 178 |
skin | 100% | 9822.22 | 1806 / 1809 | 0% | 0.02 | 2 / 472 |
kidney | 100% | 5865.75 | 89 / 89 | 0% | 0.00 | 1 / 901 |
muscle | 100% | 27636.49 | 803 / 803 | 0% | 0 | 0 / 0 |
ovary | 99% | 8195.19 | 179 / 180 | 0% | 0.01 | 2 / 430 |
blood vessel | 100% | 7249.62 | 1333 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 5395.82 | 1199 / 1204 | 0% | 0 | 0 / 0 |
thymus | 99% | 5018.34 | 645 / 653 | 0% | 0 | 0 / 605 |
prostate | 98% | 7040.10 | 241 / 245 | 0% | 0.00 | 1 / 502 |
brain | 96% | 4474.53 | 2534 / 2642 | 0% | 0 | 0 / 705 |
spleen | 93% | 2569.82 | 223 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 83% | 5528.12 | 772 / 929 | 0% | 0 | 0 / 0 |
heart | 81% | 2867.66 | 696 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030335 | Biological process | positive regulation of cell migration |
GO_0009898 | Cellular component | cytoplasmic side of plasma membrane |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005769 | Cellular component | early endosome |
GO_0005819 | Cellular component | spindle |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0004725 | Molecular function | protein tyrosine phosphatase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | PTP4A1 |
Protein name | Protein tyrosine phosphatase type IVA 1 (EC 3.1.3.48) (Protein-tyrosine phosphatase 4a1) (Protein-tyrosine phosphatase of regenerating liver 1) protein-tyrosine-phosphatase (EC 3.1.3.48) Protein tyrosine phosphatase 4A1 Protein tyrosine phosphatase type IVA 1 (EC 3.1.3.48) (PTP(CAAXI)) (Protein-tyrosine phosphatase 4a1) (Protein-tyrosine phosphatase of regenerating liver 1) (PRL-1) |
Synonyms | PRL1 PTPCAAX1 |
Description | FUNCTION: Protein tyrosine phosphatase which stimulates progression from G1 into S phase during mitosis. May play a role in the development and maintenance of differentiating epithelial tissues. Enhances cell proliferation, cell motility and invasive activity, and promotes cancer metastasis. . |
Accessions | A0A0D9SGK2 B5BU78 ENST00000673199.1 ENST00000626021.3 ENST00000639568.2 Q93096 ENST00000672924.1 ENST00000627002.1 A0A3B3ISR8 ENST00000648894.1 |